Vidal suggests tougher scrutiny for pharma patents is in the works
In some of her first public remarks, USPTO director hints at concrete actions the agency could soon take to address perceived patent abuses in life sciences
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.